NCT03446209View on ClinicalTrials.gov

Tocilizumab for the Treatment of Familial Mediterranean Fever

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 23, 2018

Primary Completion Date

October 30, 2020

Study Completion Date

October 30, 2020

Conditions
Familial Mediterranean Fever
Interventions
DRUG

Tocilizumab Infusion RoAcemtra (EU)

Experimental arm's patients will obtain TCZ intravenously once every 4 weeks for 28 weeks

DRUG

0.9% physiological saline

"Experimental arm's patients will obtain saline intravenously once every 4 weeks for 16 weeks. If necessary, patients will get rescue medication after week 16 to week 28."

Trial Locations (3)

10117

Charité Universitätsmedizin Berlin, Klinik für Rheumatologie und Klinische Immunologie, Abteilung -Neue Therapien & Studien, Berlin

50937

Universitätsklinikum Köln, Klinik I für Innere Medizin, Cologne

72076

University Hospital Tuebingen; Department of oncology, hematology, rheumatology, immunology and pulmology, Tübingen

All Listed Sponsors
lead

University Hospital Tuebingen

OTHER

NCT03446209 - Tocilizumab for the Treatment of Familial Mediterranean Fever | Biotech Hunter | Biotech Hunter